This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Connect to Quit for Smoking (CTQ)

This study has been completed.
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Pittsburgh Identifier:
First received: January 27, 2011
Last updated: February 23, 2016
Last verified: February 2016
The purpose of this research study is to examine the effectiveness of an intervention designed to reduce smoking in low income veterans within a regional United States Veterans Administration(VA) health care system. A proactive, personalized, coordinated system of care "Connect to Quit (CTQ)" is rooted in the Chronic Care Model. CTQ treats smoking as a chronic condition, like hypertension or diabetes, that requires long term treatment with appropriate combinations of behavioral therapy and pharmacotherapy. CTQ will be evaluated in the context of three (3) VA Pittsburgh Healthcare System (VAPHS) medical practices.

Condition Intervention
Smoking Smoking Cessation Other: Coordinated Care Other: Usual Care

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Connect to Quit: Coordinated Care for Smoking Cessation Among Low Income Veterans

Resource links provided by NLM:

Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:
  • Effectiveness of CTQ vs UC [ Time Frame: Two (2) year period ]
    We will measure abstinence of CTQ smokers vs those in Usual Care (UC). We will biochemically-validate (defined as salivary cotinine <10ng/ml) self reported abstinence (30 day point-prevalence) at the end of 2 years.

Enrollment: 633
Study Start Date: March 2011
Study Completion Date: February 2015
Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Usual Care
Participants will continue to receive all the care currently offered in the VAPHS, including medications for smoking cessation and use of the in-person or telephone counseling options for quit smoking classes. For veterans with a co-pay, incurred fees with be reimbursed.
Other: Usual Care
Standard therapy to help participants with smoking cessation.
Other Names:
  • Smoking, Tobacco
  • Tobacco Smoking
  • Smoking Cessation
  • Tobacco, Intervention
  • Nicotine Replacement
  • Buproprion, Wellbutrin
  • Chantix, Varenicline
  • Behavorial therapy
Active Comparator: Coordinated Care
A CTQ Coordinator will coordinate the delivery of smoking related care.
Other: Coordinated Care
CTQ coordinators will contact the participants for various information sessions about the participant's smoking. These participants will also receive our Connecting to Quit newsletter quarterly.
Other Names:
  • Smoking, Tobacco
  • Tobacco Smoking
  • Smoking Cessation
  • Tobacco, Intervention
  • Nicotine Replacement
  • Buproprion, Wellbutrin
  • Chantix, Varenicline
  • Behavorial therapy

Detailed Description:
Approximately 40 Primary Care Providers (PCPs), including non-physicians, in the VAPHS and their patients will be recruited and randomized to either Connect to Quit (CTQ) or Usual Care (UC), existing Veterans Health Administration (VHA) services. After PCPs are enrolled, we will begin recruiting their patients who meet eligibility criteria. The desire to quit smoking is not required for participation in the study, as the point of CTQ is to engage smokers at every level of readiness to quit. Target enrollment is 660 participants, approximately 330 in each treatment arm. Participants will be followed for a minimum of 2 years and a maximum of 4. Investigators will measure abstinence (biochemically-validated, 30 day point-prevalence) throughout the study, assessed every 6 months.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male or female 18 years or older
  • Veterans seen by a primary care physician within the VAPHS
  • Household income not more than $36,000 annually
  • Smoke at least 1 cigarette per day

Exclusion Criteria:

  • Smokeless tobacco (snuff or chew) users
  • Non-cigarette (e.g., pipe) smokers
  • Non-English speaking patients
  • Can not be enrolled in another smoking cessation related clinical trial at the time of enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01299896

United States, Pennsylvania
VA Pittsburgh Healthcare System
Pittsburgh, Pennsylvania, United States, 15206
Sponsors and Collaborators
University of Pittsburgh
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Principal Investigator: Hilary A. Tindle, MD, MPH Vanderbilt University
  More Information

Responsible Party: University of Pittsburgh Identifier: NCT01299896     History of Changes
Other Study ID Numbers: 02936
R01CA141596 ( U.S. NIH Grant/Contract )
Study First Received: January 27, 2011
Results First Received: January 21, 2016
Last Updated: February 23, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by University of Pittsburgh:
Cigarette Smoking
Smoking, Tobacco
Tobacco Smoking
Smoking Cessation
Tobacco Dependence

Additional relevant MeSH terms:
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Agents
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors processed this record on September 21, 2017